Targeting the epidermal growth factor receptor: prognostic and clinical implications

Oncogenic kinase signalling

2001 • 3,632 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

EGFR and cancer prognosis

2001 • 2,068 citations

Growth Factors and Cancer

1991 • 2,044 citations

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

2001 • 988 citations

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

2000 • 934 citations

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 • 828 citations

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 • 764 citations

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

2001 • 642 citations

Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.

1995 • 633 citations

Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

2003 • 616 citations

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

2002 • 583 citations

Prognostic Factors in Non-small Cell Lung Cancer

2002 • 563 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 490 citations

Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

2000 • 394 citations

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

2003 • 271 citations

A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC)

2001 • 194 citations

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer

2000 • 158 citations

Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review

2000 • 124 citations

O-244 Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor

2003 • 23 citations